Michael Klichinsky is the co-founder and chief scientific officer of Carisma Therapeutics, which is developing macrophage-based cell therapies for cancer.
November 7, 2023 10:23 AM ESTUpdated 11:53 AM
Cell/Gene Tx
In Focus

mR­NA’s next trick? Re­pro­gram­ming off-the-shelf cell ther­a­pies for can­cer and au­toim­mune dis­eases

Ryan Cross

Senior Science Correspondent

Lei Lei Wu

News Reporter

A hand­ful of biotechs, in­clud­ing Mod­er­na, are bet­ting that sim­ple in­fu­sions with mR­NA could su­per­charge im­mune cells to fight can­cer and oth­er dis­eases in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Roche's new treat­ment for sub­set of breast can­cer pa­tients

Eli Lil­ly inks an­oth­er obe­si­ty pact, dou­bling down on small Swiss part­ner

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Sev­en pa­tients di­ag­nosed with blood can­cer af­ter Skysona treat­ment, new da­ta show

Grit­stone files for bank­rupt­cy, says it could forge a trans­ac­tion as ear­ly as this month to keep R&D go­ing

Im­mat­ics heads to Phase 3 with melanoma cell ther­a­py, seeks to raise $150M

A service from the Financial Times